| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
NF-kappaB, NLRP3/AIM2. Obovatol is a potent inhibitor of NF-kappaB, suppressing the translocation of p50 and p65 into the nucleus and inhibiting the DNA-binding activity of NF-kappaB in LPS-treated RAW264.7 cells. It also targets the PANoptosis-related molecule NLRP3/AIM2. Additionally, it inhibits the DNA-binding activity of NF-kappaB induced by LPS, suppresses IkappaB release, and inhibits COX-1 and LOX activities. Obovatol binds to Prx2 and enhances its peroxidase activity, down-regulating LPS/TLR4 signaling.
|
|---|---|
| ln Vitro |
Obovatol has broad biological activities including antioxidant, neuroprotective, anti-inflammatory, anti-thrombotic, anti-fungal (IC50=38 microM against Cryptococcus neoformans), and anti-tumor activities. It enhances docetaxel-induced prostate and colon cancer cell death through inactivation of NF-kappaB. It also acts as a chitin synthase inhibitor and potentiates pentobarbital-induced sleep time through GABAA receptor/chloride channel activation. Obovatol increases the expression of GABAA receptor subunits.
|
| ln Vivo |
Obovatol has been studied in various animal models. It enhances pentobarbital-induced sleeping time in mice through GABAA receptors/chloride channel activation. It attenuates scopolamine-induced cognitive dysfunction by reducing Abeta accumulation and beta-secretase activity in the cortex and hippocampus of mice. Obovatol reduces neuroinflammation, oxidative stress, and neuronal loss in Alzheimer's disease models. It also shows anti-platelet activity in vivo through inhibition of COX-1 and LOX.
|
| Enzyme Assay |
Not explicitly detailed in reference sources. A typical NF-kappaB binding assay involves incubating nuclear extracts from LPS-treated cells with a biotinylated NF-kappaB consensus DNA probe and Obovatol. DNA binding activity is measured by EMSA or ELISA. Alternatively, the interaction of Obovatol with Prx2 is studied by surface plasmon resonance or pull-down assays with recombinant protein.
|
| Cell Assay |
RAW264.7 cells are treated with LPS (1 microg/mL) to activate NF-kappaB, with or without Obovatol pretreatment for 1 hour. NF-kappaB p65 translocation to the nucleus is detected by immunofluorescence or Western blot of nuclear fractions. NF-kappaB DNA-binding activity is measured in nuclear extracts using an ELISA-based assay. iNOS and COX-2 expression, as well as pro-inflammatory cytokine levels, are measured by Western blot or ELISA.
|
| Animal Protocol |
In the mouse pentobarbital-induced sleep model, Obovatol is administered intraperitoneally or orally 30 minutes before pentobarbital injection, and sleep duration is recorded. In the scopolamine-induced cognitive dysfunction model, Obovatol is administered daily for 7-14 days before scopolamine injection. Cognitive function is assessed by Morris water maze or passive avoidance test, and brain tissue is analyzed for Abeta levels, beta-secretase activity, and markers of cholinergic function.
|
| ADME/Pharmacokinetics |
Obovatol has a molecular weight of 282.33 and formula C18H18O3. It is soluble in DMSO and ethanol. For in vivo studies, it can be formulated in various vehicles. Storage should be at -20degC as powder, where it is stable for up to 3 years. In solution at -80degC, it is stable for up to 1 year. The compound should be protected from light and moisture.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data for Obovatol are provided in the reference sources. As a natural product isolated from Magnolia obovata, which has a history of traditional use, Obovatol may have a favorable safety profile at certain doses. However, comprehensive toxicological studies would be required for therapeutic development. The compound is for research use only.
|
| References | |
| Additional Infomation |
Obovatol has reportedly been found in magnolias (Magnolia officinalis), Magnoliaceae, and other organisms with available data.
Obovatol is a natural product and research compound, not approved for clinical use. It has been extensively studied for its multiple biological activities, including anti-inflammatory, neuroprotective, anti-cancer, and anti-fungal effects. Its ability to cross the blood-brain barrier and reduce Abeta accumulation makes it a potential candidate for Alzheimer's disease research. The compound is a valuable tool for studying NF-kappaB inhibition, PANoptosis, and neuroinflammation. |
| Molecular Formula |
C18H18O3
|
|---|---|
| Molecular Weight |
282.33372
|
| Exact Mass |
282.126
|
| CAS # |
83864-78-2
|
| PubChem CID |
100771
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.149g/cm3
|
| Boiling Point |
413.6ºC at 760 mmHg
|
| Flash Point |
203.9ºC
|
| Index of Refraction |
1.601
|
| LogP |
4.347
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
333
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1C(O)=C(OC2C=CC(CC=C)=CC=2)C=C(CC=C)C=1
|
| InChi Key |
OPGPFZQBCIAFLI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H18O3/c1-3-5-13-7-9-15(10-8-13)21-17-12-14(6-4-2)11-16(19)18(17)20/h3-4,7-12,19-20H,1-2,5-6H2
|
| Chemical Name |
5-prop-2-enyl-3-(4-prop-2-enylphenoxy)benzene-1,2-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~708.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (17.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (17.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (17.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5420 mL | 17.7098 mL | 35.4195 mL | |
| 5 mM | 0.7084 mL | 3.5420 mL | 7.0839 mL | |
| 10 mM | 0.3542 mL | 1.7710 mL | 3.5420 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
